Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Akaal Pharma has completed recruitment for a Phase 2 clinical trial of topical AKP‑119 in atopic dermatitis with pruritus. Previous Phase 1a/1b studies showed safety and efficacy signals in atopic dermatitis and psoriasis. Lead candidates Takp‑119 and Oakp‑11 are differentiated S1P₁ modulators with high selectivity, strong activity, minimal lymphopenia, cardiovascular safety, and favorable PK profile.
Top-line data from the ongoing Phase 2 study expected Q3/Q4 of 2024.
Preclinical programs target neuropathic pain and autoimmune skin diseases.
The company holds patents on S1P receptor modulators for autoimmune disease applications.
Pipeline breadth includes at least four programs across various stages targeting immune-mediated conditions.
No commercialized products as of June 2025.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Akaal Pharmacy.